Will Garner

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax, Anton Pozniak, Marisa Montes et al. · The Lancet · 2017 · 395 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study

Emmanuel Gonzalès, Winita Hardikar, Michael Stormon et al. · The Lancet · 2021 · 169 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Anton Pozniak, Martin Markowitz, Anthony Mills et al. · The Lancet Infectious Diseases · 2014 · 99 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

Oliver A. Cornely, Thibaut Leguay, Johan Maertens et al. · Journal of Antimicrobial Chemotherapy · 2017 · 88 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

Joel E. Gallant, Jason Brunetta, Gordon Crofoot et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2016 · 70 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17